MedTrace Logo

Melatonin Treatment for Tardive Dyskinesia in Schizophrenia

NCT01391390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-07-12

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120 patients with established tardive dyskinesia (TD). This study addresses a free radical hypothesis of TD.

Conditions

  • Tardive Dyskinesia

Interventions

DRUG

Melatonin

10mg/day, 12-week treatment

DRUG

Placebo

10mg/day, 12-week treatment for TD

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Lian Y Cao, MD · Beijing HuiLongGuan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01391390 on ClinicalTrials.gov